CPS
  • Home

Sign in or register to track your progress, save, and view your completed history.

Breast Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head & Neck Cancer, Lung Cancer, Urothelial Cancer

Podcast Episode 1: A Look Behind the Scenes - Extracting Cutoff and Scoring Algorithms from Clinical Data

    clockimg 35m
  • Podcast
  • Foundational
 saveimgSave unsaveimgUnsave

In this inaugural episode of the "Dialogues in CDx" podcast series, you’ll hear about the intricate relationship between diagnostic cutoffs and clinical data. In the PD-L1 space, there are multiple scoring algorithms, cutoffs, assays, and staining platforms for various indications, leading to frustration among pathologists. This episode centers around the question "Why is the PD-L1 domain so complex”? To answer this, the origins of cutoffs and algorithms, and how they are applied to the right patients, are explored. 

 

To discuss the topic, host Scott W. Boyer is joined by two esteemed guests, one representing the perspective of the pathologist working in clinical practice, and the other representing the perspective of the industry that develops CDx assays.   

 

Dr. Hans-Ulrich Schildhaus is Executive Vice President of Pathology and Medical Affairs at Discovery Life Sciences Biomarker Services, as well as Medical Director and one of the Managing Directors of Pathology Nordhessen. Dr. Douglas Clark is the Chief Pathologist in the CDx Division at Agilent Technologies. He has expertise in pathology artificial intelligence, cytopathology, and molecular diagnostics.  

 

The topics covered in this conversation include: 

  • Reconciling diagnostic algorithms and cutoffs with real-life clinical data
  • How therapy mechanism of action impacts scoring algorithm development 
  • The necessity of multiple cutoffs  
  • Experiences with real-world reproducibility 
  • Establishing trust in PD-L1 scoring 
  • The influence of digital pathology on future scoring algorithms and cutoffs 

Dr. Hans-Ulrich Schildhaus​, Prof. Dr. med.

University Hospital Essen & West German Cancer Center Essen

Dr. Douglas P. Clark

Chief Pathologist, CDx Division Agilent Technologies

Scott Boyer, PhD, MBA

Global Product Manager, Agilent Technologies

Related Training

 

The views and opinions expressed by the guests on this podcast are their own and do not necessarily reflect the views or opinions of the host or of Agilent.

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.D0130685_1.00